相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- Incendia Therapeutics reported encouraging Phase 1 results for PRTH-101, a first-in-class DDR1-targeted antibody, achieving 7.9 months median progression-free survival in thymic epithelial carcinoma patients. - The therapy demonstrated particular efficacy in patients with high DDR1 expression, with two confirmed partial responses and multiple patients showing prolonged stable disease beyond published expectations. - A pivotal Phase 2 registrational trial comparing PRTH-101 plus pembrolizumab to pembrolizumab alone is planned for 2026, targeting patients with recurrent or metastatic thymic epithelial carcinoma. - PRTH-101 works by disrupting tumor-associated collagen barriers to enable immune cell penetration into the tumor core, potentially transforming treatment for immune-excluded solid tumors.
• DELFI Diagnostics' DELFI-TF assay will be used in Incendia Therapeutics' Phase 1 clinical trial (NCT05753722) to evaluate treatment response and disease progression. • The DELFI-TF assay offers a cost-effective method for monitoring circulating cell-free DNA (cfDNA) with a small plasma volume requirement. • Incendia Therapeutics is developing innovative therapeutics that reprogram the tumor microenvironment (TME) for precision medicine. • The collaboration aims to enhance patient outcomes by leveraging DELFI's advanced detection tools for efficient drug development.
- Incendia Therapeutics has dosed the first patient in a Phase Ic trial of PRTH-101, a novel DDR1 inhibitor, for advanced or metastatic solid tumors. - The open-label study will evaluate PRTH-101's safety, tolerability, and anti-tumor activity as a monotherapy and in combination with pembrolizumab. - The trial aims to enroll up to 270 patients in the US and will determine optimal dosing for future Phase II clinical programs. - The study will also investigate DDR1 and related proteins as potential biomarkers for patient response to PRTH-101 treatment.
